Skip to main content
See the bias in every story
Published • loading... • Updated

Avvisa Prohibits the Sale of Irregular Insulin and Tirzepatide

Summary by EBC
Open the article to view the coverage from EBC
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

13 Articles

Rmcarvalho/Getty Images The National Agency for Health Surveillance (Anvisa) banned the marketing of insulin glargine distributed irregularly and determined the seizure of six products sold over the internet as peptides and medicines.The measures were published on Tuesday (6/10) and involve products without sanitary regularization in Brazil.In the case of insulin, the prohibition applies to all lots of glargine of 3 mL/100 IU distributed by the …

·Brasília, Brazil
Read Full Article
Portal Manaus AlertaPortal Manaus Alerta
+5 Reposted by 5 other sources

The National Agency of Health Surveillance (Anvisa) banned the sale and use of all lots of insulin produced by the company Costa Mar Comércio Licitatorio. The decision was published on Tuesday (6) in the Official Journal of the Union. In a note, Anvisa informed that the company distributed insulin glargina 3 mL/100 IU without authorisation [...] Read more in Anvisa forbids sale of insulin and irregular tirzepatida - Portal Manaus Alerta.

After identifying irregularities, Anvisa prohibits medicines and products sold without registration or authorisation, including insulin and tirzepatide The post Anvisa prohibits insulin, tirzepatide and other products sold irregularly; see what enters the list apareceu primeiro em ND More

In a note, Anvisa informed that the company distributed insulin glargina 3 mL/100 IU without the Company Operating Authorization (AFE) for the activity, in disagreement with the current health legislation.

Open the article to view the coverage from A TARDE

The National Agency of Health Surveillance (Anvisa) banned the sale and use of all lots of insulin produced by the company Costa Mar Comércio Licitório.The decision was published on Tuesday (6) in the Official Journal of the Union.In a note, Anvisa informed that the company distributed insulin glargina 3 mL/100 IU without the Company Operating Authorization (AFE) for the activity, in disagreement with the existing health legislation.Inspection c…

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Poder360 broke the news on Tuesday, October 6, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal